Insmed to Participate at November Investor Conferences
Nov 14, 2016 13:01 pm UTC| Business
BRIDGEWATER, N.J., Nov. 14, 2016 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that the company will participate at...
Nov 14, 2016 13:01 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- The Wall Street Journal today launched a redesigned newspaper, showcasing the most compelling daily package of business, economic and financial news, complimented by incisive features and...
Nov 14, 2016 13:01 pm UTC| Business
NEW YORK, Nov. 14, 2016 -- The Wall Street Journal today launched a redesigned newspaper, showcasing the most compelling daily package of business, economic and financial news, complimented by incisive features and...
Nov 14, 2016 13:01 pm UTC| Business
-- CB 2679d/ISU304 Demonstrates Beneficial Effect in Hemophilia B Murine Models Using Subcutaneous Dosing -- -- Subcutaneous Phase 1/2 Proof-of-Concept Clinical Trial of High-Potency Factor IX CB 2679d/ISU304 in...
Nov 14, 2016 13:01 pm UTC| Business
-- CB 2679d/ISU304 Demonstrates Beneficial Effect in Hemophilia B Murine Models Using Subcutaneous Dosing -- -- Subcutaneous Phase 1/2 Proof-of-Concept Clinical Trial of High-Potency Factor IX CB 2679d/ISU304 in...
CoLucid Pharmaceuticals Provides SPARTAN Enrollment Update
Nov 14, 2016 13:01 pm UTC| Business
Comparison of 50 mg, 100 mg and 200 mg of lasmiditan oral tablets to placebo for the acute treatment of migraineOver 50% of the expected 2,968 migraine patients enrolled77% of patients enrolled to date have multiple...
CoLucid Pharmaceuticals Provides SPARTAN Enrollment Update
Nov 14, 2016 13:01 pm UTC| Business
Comparison of 50 mg, 100 mg and 200 mg of lasmiditan oral tablets to placebo for the acute treatment of migraineOver 50% of the expected 2,968 migraine patients enrolled77% of patients enrolled to date have multiple...